Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Starna
Suzhou, Jiangsu, Chinastarnatx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Starna Therapeutics is a biotechnology company specializing in the development of next-generation RNA therapeutics using its proprietary STAR (Selective Tissue-targeting RNA) platform. The company focuses on mRNA and circular RNA (circRNA) technologies, coupled with advanced lipid nanoparticle (LNP) delivery systems that enable extrahepatic targeting. Starna's pipeline includes programs for infectious diseases, oncology, and rare genetic disorders. By optimizing RNA stability and tissue specificity, the company aims to overcome current limitations in RNA drug delivery and expression.
- Therapeutic areas
- Infectious DiseasesRare DiseasesMetabolic DisordersOncology
- Modalities
- mRNA-based drugsRNA therapyLipid nanoparticle delivery therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Starna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Starna.